Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,065 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tirzepatide ameliorates eating behaviors regardless of prior exposure to glucagon-like peptide receptor agonists in Japanese patients with type 2 diabetes mellitus.
Suzuki T, Sato T, Tanaka M, Endo K, Nakata K, Ogawa T, Hosaka I, Akiyama Y, Umetsu A, Furuhashi M. Suzuki T, et al. Among authors: nakata k. J Diabetes Complications. 2024 Jul;38(7):108779. doi: 10.1016/j.jdiacomp.2024.108779. Epub 2024 May 29. J Diabetes Complications. 2024. PMID: 38833854 Free article.
Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats.
Oshima H, Miki T, Kuno A, Mizuno M, Sato T, Tanno M, Yano T, Nakata K, Kimura Y, Abe K, Ohwada W, Miura T. Oshima H, et al. Among authors: nakata k. J Pharmacol Exp Ther. 2019 Mar;368(3):524-534. doi: 10.1124/jpet.118.253666. Epub 2018 Dec 14. J Pharmacol Exp Ther. 2019. PMID: 30552292
Canagliflozin, a sodium-glucose cotransporter 2 inhibitor, normalizes renal susceptibility to type 1 cardiorenal syndrome through reduction of renal oxidative stress in diabetic rats.
Kimura Y, Kuno A, Tanno M, Sato T, Ohno K, Shibata S, Nakata K, Sugawara H, Abe K, Igaki Y, Yano T, Miki T, Miura T. Kimura Y, et al. Among authors: nakata k. J Diabetes Investig. 2019 Jul;10(4):933-946. doi: 10.1111/jdi.13009. Epub 2019 Feb 25. J Diabetes Investig. 2019. PMID: 30663266 Free PMC article.
mTORC1 inhibition attenuates necroptosis through RIP1 inhibition-mediated TFEB activation.
Abe K, Yano T, Tanno M, Miki T, Kuno A, Sato T, Kouzu H, Nakata K, Ohwada W, Kimura Y, Sugawara H, Shibata S, Igaki Y, Ino S, Miura T. Abe K, et al. Among authors: nakata k. Biochim Biophys Acta Mol Basis Dis. 2019 Dec 1;1865(12):165552. doi: 10.1016/j.bbadis.2019.165552. Epub 2019 Sep 6. Biochim Biophys Acta Mol Basis Dis. 2019. PMID: 31499159 Free article.
Metabolic dysfunction-associated steatotic liver disease (SLD) and alcohol-associated liver disease, but not SLD without metabolic dysfunction, are independently associated with new onset of chronic kidney disease during a 10-year follow-up period.
Mori K, Tanaka M, Sato T, Akiyama Y, Endo K, Ogawa T, Suzuki T, Aida H, Kawaharata W, Nakata K, Hosaka I, Umetsu A, Hanawa N, Furuhashi M. Mori K, et al. Among authors: nakata k. Hepatol Res. 2024 Aug 7. doi: 10.1111/hepr.14097. Online ahead of print. Hepatol Res. 2024. PMID: 39110552
2,065 results